Jerome Becquart JEROME BECQUART is founder and CEO of Brainvectis. He has 20 years’ industrial experience in pharmaceutical research and development at Aventis (now Sanofi) where he held different management positions in the biotechnology and lead discovery departments and as a member of the Paris research Center.

Since 2004, his entrepreneur experience includes the creation of biotech startups specialized in drug development (in metabolic and neurological diseases) and in services to the pharmaceutical industry. As a consultant, Jérôme advised many different companies in the biotech field. Jérôme graduated from Ecole Centrale Paris and obtained his PhD in biochemistry from Paris university.

Jerome Becquart, PhD

CHIEF EXECUTIVE OFFICER

NATHALIE CARTIER-LACAVE is founder and CSO of BrainVectis.

Research Director at INSERM, where she leads the group “Biotherapies of neurodegenerative diseases”, Nathalie is president of the European Society of Gene and Cell Therapy (ESGCT).

Her research led to the first gene therapy clinical trial in humans, using HIV as a gene transfer vector (Science 2009). Thanks to this trial, four children suffering from adrenoleukodystrophy were cured.

She has been interested in the link between cholesterol and neurodegenerative diseases for 10 years.

Nathalie Cartier-Lacave, MD

CHIEF SCIENTIST OFFICER

Sandro AlvesSANDRO ALVES, PhD, 12 year-expertise in research for neurodegenerative disorders and gene therapy, is director of preclinical studies at Brainvectis.

Sandro leads the Brainvectis Preclinical Research Office and directs the preclinical activity on Alzheimer’s disease and Huntington’s disease. He is also involved in the scientific consideration of future therapeutic strategies to be developed in other neurodegenerative disorders.

Prior to joining Brainvectis, Sandro conducted his research at the Brain and Spine Institute (Paris), evaluating therapeutic strategies in animal models of Spinocerebellar ataxia and then at MIRCen/CEA, developing therapeutic research in animal models of Alzheimer’s and Huntington’s disease.

Sandro obtained his PhD in Health Sciences and Technology (Neuroscience) from the Center for Neuroscience and the Faculty of Pharmacy of the University of Coimbra (Portugal), in 2008, where he developed gene therapy correction in animal models of Machado-Joseph disease.

Sandro Alves, PhD

DIRECTOR, PRECLINICAL RESEARCH

Benedikt Timmerman, PhD

Sandro AlvesSANDRO ALVES, PhD, 12 year-expertise in research for neurodegenerative disorders and gene therapy, is director of preclinical studies at Brainvectis.

Sandro leads the Brainvectis Preclinical Research Office and directs the preclinical activity on Alzheimer’s disease and Huntington’s disease. He is also involved in the scientific consideration of future therapeutic strategies to be developed in other neurodegenerative disorders.

Prior to joining Brainvectis, Sandro conducted his research at the Brain and Spine Institute (Paris), evaluating therapeutic strategies in animal models of Spinocerebellar ataxia and then at MIRCen/CEA, developing therapeutic research in animal models of Alzheimer’s and Huntington’s disease.

Sandro obtained his PhD in Health Sciences and Technology (Neuroscience) from the Center for Neuroscience and the Faculty of Pharmacy of the University of Coimbra (Portugal), in 2008, where he developed gene therapy correction in animal models of Machado-Joseph disease.

BUSINESS DEVELOPMENT, BOARD MEMBER

Scientific advisers


Jocelyne Caboche, PhD, research Director (INSERM/UMR-S 1130, CNRS/UMR 8246)
Alexandra Durr, MD, PhD, clinical reference centre for HD and SCA. ICM, Pitié-Salpêtrière Hospital, Paris
Michel Zerah, MD neurosurgeon, Necker Hospital, Paris
Nicolas Ferry, MD, PhD, Regulatory consultant. Ex ANSM director of advanced therapies

Enregistrer

Enregistrer

Enregistrer